, 20-measurments, each 8sec; EPI (diffusion) small FOV (VS 1.5x1.5x3.5mm 3 , b=0, 50, 150, 500, 800, 1200 s/mm²; ADC and b2000 were extrapolated, for ADC a mono-exponential fit was employed; Dixon-VIBE whole-pelvis sequence (VS 1.1x1.1x1.3mm 3 ), in some cases 1H-MRS using chemical shift imaging on a prostate only FOV. Most scans for staging and planning before IRE were carried out with an endo-rectal coil (MEDRAD eCoil 1.5). In some cases, external MRI with different parameters were used if they were deemed of acceptable quality and the patient refused a repeat MRI. 24h postprocedure MRI was optimized for treatment zone delineation (VIBE DCE and Dixon-VIBE, v.s.), and exclusion of hemorrhage and organ damage (rectum, bladder, etc.). This protocol comprised the same sequences but with adjustments to the use without an endo-rectal coil. Most follow-up MRIs, particularly those for exclusion of recurrences were performed with an endo-rectal coil employing the same protocol. The evaluation was performed in accordance to PI-RADS v1 and v2 until and after January 2016, respectively.
3D-Mapping Biopsy
The procedure was carried out under full anesthesia (TIVA) in lithotomy position with with a stepper and brachytherapy grid (CIVICO medical solutions) placed in front of the perineum under US (BK 2 Medical Flex Focus 300 or BK3000) guidance. Biopsies (Uromed Kurt Drews KG) of 15 or 22 mm length were taken through the perineum every 5 mm (spacing of the grid) inside the prostate. The matrix was a 5mm spaced brachygrid for X and Y axis orientation. X, y and z-coordinates of each biopsy were recorded, affording a color-coded (for Gleason-score) 3D-histopathological model to be reconstructed from the results using a custom programmed computer software, with US and MRI cut-plane overlays. When deemed necessary, additional cognitive fusion biopsies were obtained. Left: green = last data point acquired less than 6 months after IRE, yellow = 6 to 12 months, orange = one to two years, blue over 2 years after IRE. Right: Patients grouped in most recent follow-up periods and follow-up modality. Inner circle: last data point acquired less than 6 months after IRE, second circle: 6 to 12 months, third circle one to two years, outer circle over 2 years of follow-up post IRE. Colors indicate follow-up modality; green MRI, purple PSA, blue either MRI or PSA, red more than one follow-up data point and last data point not over 12 months prior cut-off. 
Follow-up

